BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 18837728)

  • 1. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
    Bongiorno MR; Pistone G; Doukaki S; Aricò M
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S15-20. PubMed ID: 18837728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
    Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
    Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
    Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT; Adorni G
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.
    Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P
    Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of psoriasis with adalimumab.
    Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM
    Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient.
    Lindsey SF; Weiss J; Lee ES; Romanelli P
    J Drugs Dermatol; 2014 Jul; 13(7):869-71. PubMed ID: 25007373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week).
    Nanke Y; Kobashigawa T; Sugimoto N; Yamanaka H; Kotake S
    Immunol Med; 2019 Jun; 42(2):99-102. PubMed ID: 31446856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
    Mease PJ; Ory P; Sharp JT; Ritchlin CT; Van den Bosch F; Wellborne F; Birbara C; Thomson GT; Perdok RJ; Medich J; Wong RL; Gladman DD
    Ann Rheum Dis; 2009 May; 68(5):702-9. PubMed ID: 18684743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.
    Ardigò M; Giuliani A; de Felice C; Mastroianni A; Berardesca E
    J Drugs Dermatol; 2008 Oct; 7(10):935-9. PubMed ID: 19112756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biological treatment of psoriasis and psoriatic arthritis].
    Kragballe K; Deleuran B
    Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
    Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.